These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 16690374

  • 1. Current opinion on inhibitor treatment options.
    Mathew P.
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
    [Abstract] [Full Text] [Related]

  • 2. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [Abstract] [Full Text] [Related]

  • 3. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA.
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [Abstract] [Full Text] [Related]

  • 4. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G, Shafer FE, Rojas P, Seremetis S.
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [Abstract] [Full Text] [Related]

  • 5. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M, Lambert T.
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [Abstract] [Full Text] [Related]

  • 6. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
    Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE.
    Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
    [Abstract] [Full Text] [Related]

  • 7. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P.
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [Abstract] [Full Text] [Related]

  • 8. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
    Brackmann HH, Effenberger W, Hess L, Schwaab R, Oldenburg J.
    Eur J Haematol Suppl; 1998 Jun; 63():18-23. PubMed ID: 9882928
    [Abstract] [Full Text] [Related]

  • 9. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I.
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [Abstract] [Full Text] [Related]

  • 10. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
    Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA.
    Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
    [Abstract] [Full Text] [Related]

  • 11. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM.
    Semin Thromb Hemost; 2000 May; 26(2):179-88. PubMed ID: 10919411
    [Abstract] [Full Text] [Related]

  • 12. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
    Steen Carlsson K, Astermark J, Donfield S, Berntorp E.
    Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
    [Abstract] [Full Text] [Related]

  • 13. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M, Coppola A, Tagliaferri A, Lippi G.
    Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.
    Zhou ZY, Hay JW.
    Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208
    [Abstract] [Full Text] [Related]

  • 15. FEIBA safety profile in multiple modes of clinical and home-therapy application.
    Luu H, Ewenstein B.
    Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
    [Abstract] [Full Text] [Related]

  • 16. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW, Lee SY, Park SK.
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [Abstract] [Full Text] [Related]

  • 17. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors.
    Gomperts ED, Astermark J, Gringeri A, Teitel J.
    Blood Rev; 2008 Feb; 22 Suppl 1():S1-11. PubMed ID: 18485996
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V, Núñez R, Romero JA, Montoro B, Espinós B.
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [Abstract] [Full Text] [Related]

  • 19. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
    Stewart AJ, Hanley JP, Ludlam CA.
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
    [Abstract] [Full Text] [Related]

  • 20. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
    Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF.
    Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.